Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.

PURPOSE To compare the efficacy and local toxicity of the intravesical instillation of a cytostatic drug versus the same cytostatic agent in combination with local hyperthermia as an adjuvant treatment, after complete transurethral resection (TURB) of superficial transitional cell carcinoma (TCC) of the bladder. PATIENTS AND METHODS The study was designed as a prospective, multicentric, randomized trial. Eighty-three patients suffering from primary or recurrent superficial (Ta-T1) TCC of the bladder, after a complete TURB, were randomly assigned to receive intravesical instillations of mitomycin C (MMC) alone, for 41 patients, and MMC in combination with local microwave-induced hyperthermia, for 42 patients. For the combined approach, a new system, Synergo101-1 (Medical Enterprises, Amsterdam, the Netherlands) was used. The effectiveness evaluation end points of the study were evaluation of recurrence-free survival and the estimated probability of recurrence. The safety evaluation end points included subjective and objective side effects and clinical complications. For the efficacy end point, Kaplan-Meier analysis was employed, with the log-rank test for significance. Minimum follow-up time was 24 months. RESULTS Of the 83 randomly assigned patients, 75 completed the study according to the protocol and had valid cystoscopy results. Survival analysis of the 75 assessable patients demonstrated a highly significant difference in the survival curves in favor of thermochemotherapy. Subjective intolerance and clinical complications were significantly higher but transient and moderate in the combined treatment group. CONCLUSION In our series, endovesical thermochemotherapy appears to be more effective than standard endovesical chemotherapy as an adjuvant treatment for superficial bladder tumors at 24-month follow-up, despite an increased but acceptable local toxicity.

[1]  F. Montorsi,et al.  Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. , 2001, British journal of clinical pharmacology.

[2]  S. Naito,et al.  Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: A prospective randomized study , 2001, International journal of urology : official journal of the Japanese Urological Association.

[3]  J. Chin,et al.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. , 2001, Journal of the National Cancer Institute.

[4]  S. Almenar,et al.  The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. , 2000, The Journal of urology.

[5]  S. Krege,et al.  Therapy of Superficial Bladder Carcinomas , 1999, Urologia Internationalis.

[6]  D. Lamm.  Preventing Progression and Improving Survival with BCG Maintenance , 1999, European Urology.

[7]  Richard Sylvester,et al.  Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer , 1999 .

[8]  A. Lembo,et al.  Intravesical Instillation of Mitomycin-C in 242 Patients with Superficial Bladder Cancer at High Risk of Recurrence: Long-Term Results , 1999, Urologia Internationalis.

[9]  B. Norlén,et al.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.

[10]  A. Salonia,et al.  LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TUMORS , 1998 .

[11]  S. Krege,et al.  A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. , 1996, The Journal of urology.

[12]  M. Parmar,et al.  The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. , 1996, The Journal of urology.

[13]  P. Rigatti,et al.  Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. , 1996, The Journal of urology.

[14]  N. Walach,et al.  Long‐term follow‐up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C , 1995, Journal of surgical oncology.

[15]  U. Nseyo,et al.  Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. , 1995, The Journal of urology.

[16]  P. Rigatti,et al.  A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. , 1995, The Journal of urology.

[17]  J. Drago,et al.  Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. , 1991, Cancer research.

[18]  F. Torti,et al.  Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. , 1991, Journal of the National Cancer Institute.

[19]  D. Hauri,et al.  Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. , 1990, British journal of urology.

[20]  C. Lee,et al.  Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. , 1989, The Journal of urology.

[21]  Y. Horn,et al.  Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder , 1989, Journal of surgical oncology.

[22]  E. Hall,et al.  The oncogenic potential of a combination of hyperthermia and chemotherapy agents. , 1988, British Journal of Cancer.

[23]  D. Newling,et al.  Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours. , 1987, British journal of urology.

[24]  R. Elton,et al.  Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. , 1986, British journal of urology.

[25]  J. Meyer,et al.  The clinical efficacy of localized hyperthermia. , 1984, Cancer research.

[26]  H. Huland,et al.  Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. , 1984, The Journal of urology.

[27]  B. Issell,et al.  Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa , 1984, Cancer.

[28]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[29]  J. E. Newsam,et al.  Hyperthermic perfusion of the distended urinary bladder in the management of recurrent transitional cell carcinoma. A review after 6 years. , 1982, British journal of urology.

[30]  J. Marmor.  Interactions of hyperthermia and chemotherapy in animals. , 1979, Cancer research.

[31]  G. Hahn.  Potential for therapy of drugs and hyperthermia. , 1979, Cancer research.

[32]  J. Towler,et al.  Hyperthermia in the treatment of bladder tumours. , 1976, British journal of urology.

[33]  J. E. Newsam,et al.  Hyperthermic perfusion of the distended urinary bladder in the management of recurrent transitional cell carcinoma. , 1975, British journal of urology.

[34]  H. Hisazumi,et al.  Enhanced radioinduced cytotoxicity of cultured human bladder cancer cells using 43°C hyperthermia or anticancer drugs , 2004, Urological Research.

[35]  R. Badalament,et al.  Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer , 2004, Cancer Chemotherapy and Pharmacology.

[36]  R. Badalament,et al.  Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M. Marberger,et al.  Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. , 1992, European urology.

[38]  P. Rigatti,et al.  Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. , 1991, European urology.

[39]  T S Herman,et al.  Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. , 1988, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[40]  R. Engelhardt.  Hyperthermia and drugs. , 1987, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.